Cargando…

The grey zone of Hyperuricemia in chronic kidney disease

Detalles Bibliográficos
Autor principal:	Dousdampanis, Periklis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512145/ https://www.ncbi.nlm.nih.gov/pubmed/28748120 http://dx.doi.org/10.1016/j.jare.2017.04.007

Ejemplares similares

To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
por: Shin, Dong Ho
Publicado: (2019)

Some light in the grey zone?
por: Bickenbach, J., et al.
Publicado: (2017)

Tregs and kidney: From diabetic nephropathy to renal transplantation
por: Dousdampanis, Periklis, et al.
Publicado: (2016)

Hyperuricemia: A non-traditional risk factor for development and progression of chronic kidney disease?
por: Kang, Duk-Hee
Publicado: (2012)

Hyperuricemia and chronic kidney disease: to treat or not to treat
por: Piani, Federica, et al.
Publicado: (2021)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Associations Between Hyperuricemia and Chronic Kidney Disease: A Review
por: Prasad Sah, Om Shankar, et al.
Publicado: (2015)

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
por: Waheed, Yousuf, et al.
Publicado: (2021)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

Joint association of hyperuricemia and chronic kidney disease with mortality in patients with chronic heart failure
por: Wang, Chi, et al.
Publicado: (2023)

Bimodal Solutions or Twice-Daily Icodextrin to Enhance Ultrafiltration in Peritoneal Dialysis Patients
por: Dousdampanis, Periklis, et al.
Publicado: (2013)

Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
por: Eleftheriadis, Theodoros, et al.
Publicado: (2017)

Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection
por: Kielstein, Jan T., et al.
Publicado: (2020)

Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease
por: Yang, Letian, et al.
Publicado: (2022)

Association between Dietary Fat Intake and Hyperuricemia in Men with Chronic Kidney Disease
por: Oku, Fumika, et al.
Publicado: (2022)

Allopurinol for prevention of progression of kidney disease with hyperuricemia
por: Pai, B. H. Santhosh, et al.
Publicado: (2013)

Grey Zone Lymphomas: Lymphomas with Intermediate Features
por: Hoeller, Sylvia, et al.
Publicado: (2012)

COVID-19: Shades of Grey
por: Naithani, Nardeep, et al.
Publicado: (2020)

Determinants of hyperuricemia in non-dialysed chronic kidney disease patients in three hospitals in Cameroon
por: Doualla, Marie, et al.
Publicado: (2018)

Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey
por: Cha, Ran-hui, et al.
Publicado: (2019)

Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study
por: Watanabe, Kimio, et al.
Publicado: (2021)

Hyperuricemia and Associated Factors in Children with Chronic Kidney Disease: A Cross-Sectional Study
por: Xu, Jie, et al.
Publicado: (2021)

Vegan Diet Is Associated with a Lower Risk of Chronic Kidney Disease in Patients with Hyperuricemia
por: Wu, Chia-Lin, et al.
Publicado: (2023)

Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
por: Liu, Ping, et al.
Publicado: (2023)

Hyperuricemia; a new look at an old problem
por: Mardani, Saeed, et al.
Publicado: (2012)

Gender Differences, Hyperuricemia and Brain Natriuretic Factor
por: Breuer, Gabriel S., et al.
Publicado: (2020)

Mechanisms Linking Hyperuricemia to Increased Cardiovascular Risk
por: Kang, Eun Ha
Publicado: (2019)

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey
por: Rodrigues, Susana G.
Publicado: (2023)

Plagiarism: Trespassing the Grey Zone Between Searching and Researching
por: Chowhan, AK, et al.
Publicado: (2013)

Detection of grey zones in inter-rater agreement studies
por: Demirhan, Haydar, et al.
Publicado: (2023)

Hyperuricemia, the heart, and the kidneys – to treat or not to treat?
por: Petreski, Tadej, et al.
Publicado: (2020)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Prevalence and Risk Factors of Hyperuricemia in Patients with Chronic Kidney Disease and Non-Alcoholic Fatty Liver
por: Golmohammadi, Sima, et al.
Publicado: (2020)

A retrospective cross-sectional study of the associated factors of hyperuricemia in patients with chronic kidney disease
por: Guo, Li-Ping, et al.
Publicado: (2020)

Hyperuricemia Is Associated with Left Ventricular Dysfunction and Inappropriate Left Ventricular Mass in Chronic Kidney Disease
por: Chiu, Tai-Hua, et al.
Publicado: (2020)

Synergistic association of hyperuricemia and hyperhomocysteinemia with chronic kidney disease in middle-aged adults and the elderly population
por: Liu, Peng-Tzu, et al.
Publicado: (2021)

Association between hyperuricemia and chronic kidney disease: a cross-sectional study in Bangladeshi adults
por: Barman, Zitu, et al.
Publicado: (2023)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Leydig cell tumor in grey zone: A case report
por: Muheilan, Muheilan Mustafa, et al.
Publicado: (2017)

Grey zone lesions of breast: Potential areas of error in cytology
por: Mitra, Suvradeep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_faagdlpa9pi173n8rm3i1bcr1v